Nutriband CEO to Highlight Abuse-Deterrent Tech at Georgia Life Sciences Summit
Event summary
- Nutriband CEO Gareth Sheridan to present at the Georgia Life Sciences Summit on August 26, 2026.
- Summit brings together leaders from biotechnology, medical technology, research, manufacturing, and investment.
- Nutriband's AVERSA™ technology aims to prevent abuse of transdermal drugs like fentanyl.
- Technology covered by patents in the U.S., Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.
The big picture
Nutriband's participation in the Georgia Life Sciences Summit underscores the growing importance of abuse-deterrent technologies in the pharmaceutical industry. As opioid abuse remains a critical public health issue, Nutriband's AVERSA™ technology could carve out a significant niche if it gains regulatory approval and market traction. The company's broad patent portfolio positions it well to capitalize on this trend, but execution will be key.
What we're watching
- Regulatory Approval
- Whether Nutriband can secure FDA approval for its abuse-deterrent fentanyl patch.
- Market Adoption
- The pace at which AVERSA™ technology is integrated into other transdermal drugs.
- Competitive Positioning
- How Nutriband differentiates itself in the crowded abuse-deterrent drug market.
Related topics